Evidence map›Paper›PMID 30149882›Full record

ReviewTrends in cancer2018

Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA.

Michael D Kessler, Nisha R Pawar, Stuart S Martin, Toni M Antalis, Timothy D O'Connor

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. The Role of lncRNA PCAT6 in Cancers.Frontiers in oncology · 2021
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael D KesslerInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore MD 21201, USA. Electronic address: michael.kessler@som.umaryland.edu.
Nisha R PawarDepartment of Medicine, University of Maryland School of Medicine, Baltimore MD 21201, USA; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD 21201, USA.
Stuart S MartinUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore MD 21201, USA.
Toni M AntalisUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore MD 21201, USA.
Timothy D O'ConnorInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore MD 21201, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore MD 21201, USA; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD 21201, USA.

Funding

Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Targeting microtubule stabilization to reduce breast tumor metastasisR01CA154624 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARTIN, STUART S · 2012 to 2023
$3.4M
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancerR01CA196988 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2017 to 2021
$1.8M
Membrane Serine Protease Activities in Protease Activated Receptor SignalingR01HL118390 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2014 to 2017
$1.5M
NCI NIH HHS R01 CA154624NCI NIH HHS R01 CA196988NCI NIH HHS T32 CA154274NHLBI NIH HHS R01 HL118390
6 · The paper itself

Abstract

Liquid biopsy, or the capacity to noninvasively isolate and analyze plasma tumor DNA (ptDNA) using blood samples, represents an important tool for modern oncology that enables increasingly safe, personalized, and robust cancer diagnosis and treatment. Here, we review advances in the development and implementation of liquid biopsy approaches, and we focus on the capacity of liquid biopsy to noninvasively detect oncological disease and enhance early detection strategies. In addition to noting the distinctions between mutation-targeted and mutation-agnostic approaches, we discuss the potential for genomic analysis and longitudinal testing to identify somatic lesions early and to guide intervention at more manageable disease stages.

Indexed as

DNA, NeoplasmAnimalsComputational BiologyComputer SimulationHumansLiquid BiopsyNeoplasmsRecurrenceDNA, Neoplasm

Identifiers

PMID30149882
PMCPMC6116552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.